HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spiked “Supplements” For Diabetes, Pain On The Rise

This article was originally published in The Tan Sheet

Executive Summary

FDA is seeing supplements spiked with Rx ingredients indicated for pain management and diabetes treatment, and needs industry help identifying violators, CFSAN head Michael Landa says.

You may also be interested in...

In Brief

Hi-Tech OTC sales fall; social media posts prompt FDA warning; FDA warns PruTect Rx about claims; study finds no DMAA in geranium oil; prebiotic recall spreads to Eco Health product; more news In Brief.

Regulatory News In Brief

FDA warns Healing Ways to register facility; Dragon Herbs warned for tradeshow materials; BNE recalls ephedra-spiked supplements; supplement flu prevention claims cross the line; more regulatory news in brief.

FDA Expects STD Claims Enforcement To Deter Future Violations

FDA will consider prosecuting executives of firms making unapproved sexually transmitted disease treatment claims for OTC drugs and nutritional products, the targets of its latest enforcement sweep.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts